# Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Source: https://nuclide.cc/trials/nct06590857/  
Nuclide record `nct06590857` (Trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Actinium-225 DOTATATE in HR-positive / HER2-negative breast cancer, run by RayzeBio, Inc., active and no longer recruiting.

## Summary

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. is a phase 1/2 interventional study registered as NCT06590857 by RayzeBio, Inc., with 16 participants enrolled, started 2024-07-19 and due to reach its primary completion in 2028-10. Interventions recorded: RYZ101 and Standard of Care Endocrine Therapy.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Also known as: TRACY-1
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06590857
- Phase: 1/2
- Setting: Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) (TRACY-1).
- Sponsor: RayzeBio, Inc.
- Enrolled: 16

## Sources

- ClinicalTrials.gov NCT06590857: https://clinicaltrials.gov/study/NCT06590857

## Connected records

- isotopes: [Actinium-225](https://nuclide.cc/isotopes/ac-225/)
- drugs: [Actinium-225 DOTATATE](https://nuclide.cc/drugs/ryz101/)
- companies: [RayzeBio (BMS)](https://nuclide.cc/companies/rayzebio/)

---
JSON: https://nuclide.cc/api/v1/entities/nct06590857.json